Literature DB >> 11729346

The role of interleukin 10 in the regulation of allergic immune responses.

I Bellinghausen1, J Knop, J Saloga.   

Abstract

Several clinical studies and animal models have shown that Th2 lymphocytes play a key role in the pathophysiology of IgE-mediated allergic immune responses like allergic rhinitis and asthma or venom anaphylaxis. Classical specific immunotherapy (SIT) that has been proven to be clinically effective can serve as a role model for immunological changes that are associated with amelioration of allergic diseases. During SIT, the Th2-dominated immune response is modified towards a Th1 response leading to a decline in allergen-specific IgE and an increase in allergen-specific IgG production. Most importantly, however, production of the immunosuppressive/-regulatory cytokine interleukin 10 (IL-10) is also induced leading to T cell tolerance and prevention of tissue inflammation. In this article the role of IL-10-producing T cells in the regulation of allergic immune responses will be discussed. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11729346     DOI: 10.1159/000049499

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  12 in total

1.  Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model.

Authors:  Taisuke Ito; Natsuho Ito; Albrecht Bettermann; Yoshiki Tokura; Masahiro Takigawa; Ralf Paus
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

Review 2.  [Mechanisms of specific immunotherapy].

Authors:  I Bellinghausen; J Knop; J Saloga
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

Review 3.  Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease.

Authors:  Shankar Subramanian Iyer; Gehong Cheng
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

4.  Involvement of programmed death-ligand 2 (PD-L2) in the development of experimental allergic conjunctivitis in mice.

Authors:  A Fukushima; T Yamaguchi; M Azuma; H Yagita; H Ueno
Journal:  Br J Ophthalmol       Date:  2006-04-13       Impact factor: 4.638

Review 5.  Allergen immunotherapy for allergic respiratory diseases.

Authors:  Antonio Cappella; Stephen R Durham
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 6.  Immunological mechanisms in specific immunotherapy.

Authors:  Carsten B Schmidt-Weber; Kurt Blaser
Journal:  Springer Semin Immunopathol       Date:  2003-10-24

7.  IL-10 Enhances IgE-Mediated Mast Cell Responses and Is Essential for the Development of Experimental Food Allergy in IL-10-Deficient Mice.

Authors:  Stephanie H Polukort; Jeffrey Rovatti; Logan Carlson; Chelsea Thompson; Jennifer Ser-Dolansky; Shannon R M Kinney; Sallie S Schneider; Clinton B Mathias
Journal:  J Immunol       Date:  2016-05-06       Impact factor: 5.422

8.  Importance of the inducible costimulator molecule for the induction of allergic immune responses and its decreased expression on T helper cells after venom immunotherapy.

Authors:  Iris Bellinghausen; Bettina Klostermann; Ingo Böttcher; Jürgen Knop; Joachim Saloga
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

9.  Exposure to High Doses of Lipopolysaccharide during Ovalbumin Sensitization Prevents the Development of Allergic Th2 Responses to a Dietary Antigen.

Authors:  Ikuko Torii; Shigeki Shimizu; Takashi Daimon; Yoshiyasu Shinohara; Tomoo Kudo; Ayuko Sato; Tohru Tsujimura
Journal:  J Toxicol Pathol       Date:  2014-08-22       Impact factor: 1.628

10.  Protocol for a randomised, double-blind, placebo-controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes.

Authors:  Esther Helen Steveling; Mongkol Lao-Araya; Christopher Koulias; Guy Scadding; Aarif Eifan; Louisa K James; Alina Dumitru; Martin Penagos; Moisés Calderón; Peter Sejer Andersen; Mohamed Shamji; Stephen R Durham
Journal:  Clin Transl Allergy       Date:  2015-12-17       Impact factor: 5.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.